Open Access Open Access  Restricted Access Subscription Access

Drugs Acting on Poly Cystic Ovary Syndrome: A Comprehensive Review

Muralinath E., Singh H. S., Vijay Digamber D, Shraddha D, Lalit Kumar S, Kalyan C., Archana Jain, Guruprasad M.

Abstract


Polycystic Ovary SYNDROME ( PCOS ) is a common endocrine disorder influencing individuals, especially women of reproductive age. PCOS is manifested by hormonal imbalances, presence of cysts on the ovaries and irregular menstrual cycles. While lifestyle modifications, namely diet. and exercise are frequently recommend. Pharmaceutical interventions can also play a critical role in managing PCOS symptoms. Met forming is a generally prescribed medication for PCOS, specifically vfor those with insult resistance. It enhances insulin sensitivity. decreasing the elevated insulin levels frequently seen in PCOS. That is why, Metformin can help in the regulation of menstrual cycles and cam help on weight management also. Clomiphene citrate is helpful in inducing ovulation in women with PCOS. It performs by blocking estrogen receptors in the Hypothalamus, resulting enhanced production of follicle _ stimulating hormone ( FSH ) and luteinizing hormone ( LH ). This activation increases the development and release of eggs from the ovaries. In a very few cases, an injectable gonadotropin, namely FSH and LH, may be administered to activate ovulation. This frequently considered if other medications namely Clomiphene are not effective. Careful monitoring is essential to minimize the risk of especially multiple pregnancy. An elevated levels of androgen are common in PCOS. Anti_ androgen namely spironolactone perform by blocking the effects of androgen on rhe skin and hair follicles. This can assist in reducing acne and excessive hair growth ( hirsutism ) associated with PCOS. Birth control pills consisting of a combination of estrogen and protesting can control menstrual cycles and reduce symptoms namely acne and hirsutism. They perform by suppressing ovulation and stabilizing vhormonal fluctuations. Thiazolidinediones enhance insulin sensitivity and can be beneficial for women along with PCOS and insulin resistance. Thiazodinediobes assists tissues regarding response in an effective manner to insulin, contributing to better blood sugar control and regulation of menstrual cycles. Incretin_ based medications ( e g., exenatide) , originally developed for type 2 diabetes, may exhibit positive effects on PCOS. These drugs increase insulin secretion and may enhance ovarian activity, though mire research is required to establish their role definitively. Finally it is concluded that before starting any medication , individuals should consult with their health care provider to estimate the most appropriate treatment plan for their unique requirements.


Full Text:

PDF

References


Ding DC, Chen W, Wang JH, Lin SZ. Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer: A population-based cohort study in Taiwan. Medicine (Baltimore). 2018 Sep;97(39):e12608. [PMC free article] [PubMed]

Zhang C, Ma J, Wang W, Sun Y, Sun K. Lysyl oxidase blockade ameliorates anovulation in polycystic ovary syndrome. Hum Reprod. 2018 Nov 01;33(11):2096-2106. [PubMed]

Norman RJ, Teede HJ. A new evidence-based guideline for assessment and management of polycystic ovary syndrome. Med J Aust. 2018 Sep 01;209(7):299-300. [PubMed]

Goyal A, Ganie MA. Idiopathic Hyperprolactinemia Presenting as Polycystic Ovary Syndrome in Identical Twin Sisters: A Case Report and Literature Review. Cureus. 2018 Jul 19;10(7):e3004. [PMC free article] [PubMed]

Albu D, Albu A. The relationship between anti-Müllerian hormone serum level and body mass index in a large cohort of infertile patients. Endocrine. 2019 Jan;63(1):157-163. [PubMed]

Spinedi E, Cardinali DP. The Polycystic Ovary Syndrome and the Metabolic Syndrome: A Possible Chronobiotic-Cytoprotective Adjuvant Therapy. Int J Endocrinol. 2018;2018:1349868. [PMC free article] [PubMed]

Puttabyatappa M, Padmanabhan V. Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome. J Mol Endocrinol. 2018 Oct 16;61(4):R161-R184. [PMC free article] [PubMed]

Hallajzadeh J, Khoramdad M, Karamzad N, Almasi-Hashiani A, Janati A, Ayubi E, Pakzad R, Sullman MJM, Safiri S. Metabolic syndrome and its components among women with polycystic ovary syndrome: a systematic review and meta-analysis. J Cardiovasc Thorac Res. 2018;10(2):56-69. [PMC free article] [PubMed]

Maya ET, Guure CB, Adanu RMK, Sarfo B, Ntumy M, Bonney EY, Lizneva D, Walker W, Azziz R. Why we need epidemiologic studies of polycystic ovary syndrome in Africa. Int J Gynaecol Obstet. 2018 Nov;143(2):251-254. [PubMed]

Carvalho LML, Dos Reis FM, Candido AL, Nunes FFC, Ferreira CN, Gomes KB. Polycystic Ovary Syndrome as a systemic disease with multiple molecular pathways: a narrative review. Endocr Regul. 2018 Oct 01;52(4):208-221. [PubMed]


Refbacks

  • There are currently no refbacks.